Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of efgartigimod (ARGX-113) in mild to moderate pemphigus vulgaris or foliaceus
2017-002333-40Phase 2Completed
- Sponsor
- argenx
- Start
- Jul 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in pemphigus vulgaris (PV) and pemphigus foliaceus (PF), sponsored by argenx. Primary endpoint: Incidence and severity of treatment-emergent adverse events and serious adverse events. Started Jul 2017; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on 2017-002333-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002333-40.